NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

轉移性Merkel氏細胞癌市場:洞察,流行病學以及2030年為止的市場預測

Metastatic Merkel Cell Carcinoma - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966703
出版日期 按訂單生產 內容資訊 英文 200 Pages
商品交期: 10個工作天內
價格
轉移性Merkel氏細胞癌市場:洞察,流行病學以及2030年為止的市場預測 Metastatic Merkel Cell Carcinoma - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 200 Pages
簡介

本報告提供世界主要7個國家(美國,歐洲5個國家(德國,西班牙,義大利,法國,及英國),日本)的轉移性Merkel氏細胞癌市場的相關調查,提供流行病學,市場規模和預測,成長要素及課題,各治療方法、各國市場分析,競爭情形,主要企業的產品等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 競爭資訊分析

第4章 市場概要

  • 2017年:整體市場佔有率
  • 2030年:整體市場佔有率

第5章 疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第6章 患者的治療過程

第7章 流行病學及患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論性根據:主要7個國家
  • 流行病學方案:主要7個國家
  • 美國流行病學
  • 歐洲5國流行病學
    • 德國流行病學
    • 法國流行病學
    • 義大利流行病學
    • 西班牙流行病學
    • 英國流行病學
  • 日本流行病學

第8章 治療流程,目前治療,及醫務

  • 治療和管理
  • 治療流程

第9章 未滿足需求

第10章 主要評估項目

第11章 市售產品

第12章 新治療方法

第13章 主要7個國家的市場分析

  • 主要調查結果
  • 市場規模
  • 各治療法的市場規模

第14章 屬性分析

第15章 主要7個國家:市場預測

  • 美國:市場規模
    • 整體市場規模
    • 各治療法市場規模
  • 歐洲5個國家:市場規模與展望
  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
  • 日本的市場規模

第16章 獲取與償付概要

第17章 KOL的見解

第18章 市場成長要素

第19章 市場障礙

第20章 附錄

  • 參考文件
  • 報告的調查手法

第21章 DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

目錄
Product Code: DIMI1106

DelveInsight's "Metastatic Merkel Cell Carcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Metastatic Merkel Cell Carcinoma , historical and forecasted epidemiology as well as the Metastatic Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Metastatic Merkel Cell Carcinoma market report provides current treatment practices, emerging drugs, Metastatic Merkel Cell Carcinoma market share of the individual therapies, current and forecasted Metastatic Merkel Cell Carcinoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Metastatic Merkel Cell Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Metastatic Merkel Cell Carcinoma Disease Understanding and Treatment Algorithm

The DelveInsight Metastatic Merkel Cell Carcinoma market report gives a thorough understanding of the Metastatic Merkel Cell Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Metastatic Merkel Cell Carcinoma .

Treatment

It covers the details of conventional and current medical therapies available in the Metastatic Merkel Cell Carcinoma market for the treatment of the condition. It also provides Metastatic Merkel Cell Carcinoma treatment algorithms and guidelines in the United States, Europe, and Japan.

Metastatic Merkel Cell Carcinoma Epidemiology

The Metastatic Merkel Cell Carcinoma epidemiology division provide insights about historical and current Metastatic Merkel Cell Carcinoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Metastatic Merkel Cell Carcinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Metastatic Merkel Cell Carcinoma Epidemiology

The epidemiology segment also provides the Metastatic Merkel Cell Carcinoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Metastatic Merkel Cell Carcinoma Drug Chapters

Drug chapter segment of the Metastatic Merkel Cell Carcinoma report encloses the detailed analysis of Metastatic Merkel Cell Carcinoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Metastatic Merkel Cell Carcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Metastatic Merkel Cell Carcinoma treatment.

Metastatic Merkel Cell Carcinoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Metastatic Merkel Cell Carcinoma treatment.

Metastatic Merkel Cell Carcinoma Market Outlook

The Metastatic Merkel Cell Carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Metastatic Merkel Cell Carcinoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Metastatic Merkel Cell Carcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Metastatic Merkel Cell Carcinoma market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Metastatic Merkel Cell Carcinoma market in 7MM.

The United States Market Outlook

This section provides the total Metastatic Merkel Cell Carcinoma market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Metastatic Merkel Cell Carcinoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Metastatic Merkel Cell Carcinoma market size and market size by therapies in Japan is also mentioned.

Metastatic Merkel Cell Carcinoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Metastatic Merkel Cell Carcinoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Metastatic Merkel Cell Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Metastatic Merkel Cell Carcinoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Metastatic Merkel Cell Carcinoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Metastatic Merkel Cell Carcinoma emerging therapies.

Reimbursement Scenario in Metastatic Merkel Cell Carcinoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Metastatic Merkel Cell Carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Metastatic Merkel Cell Carcinoma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Metastatic Merkel Cell Carcinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Metastatic Merkel Cell Carcinoma , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Metastatic Merkel Cell Carcinoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Metastatic Merkel Cell Carcinoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Metastatic Merkel Cell Carcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Metastatic Merkel Cell Carcinoma market

Report Highlights:

  • In the coming years, Metastatic Merkel Cell Carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Merkel Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Metastatic Merkel Cell Carcinoma . Launch of emerging therapies will significantly impact the Metastatic Merkel Cell Carcinoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Metastatic Merkel Cell Carcinoma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Metastatic Merkel Cell Carcinoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Metastatic Merkel Cell Carcinoma Pipeline Analysis
  • Metastatic Merkel Cell Carcinoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Metastatic Merkel Cell Carcinoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Metastatic Merkel Cell Carcinoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Metastatic Merkel Cell Carcinoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Metastatic Merkel Cell Carcinoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Metastatic Merkel Cell Carcinoma total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Metastatic Merkel Cell Carcinoma market size during the forecast period (2017-2030)?
  • At what CAGR, the Metastatic Merkel Cell Carcinoma market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Metastatic Merkel Cell Carcinoma market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Metastatic Merkel Cell Carcinoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Metastatic Merkel Cell Carcinoma ?
  • What is the historical Metastatic Merkel Cell Carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Metastatic Merkel Cell Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Metastatic Merkel Cell Carcinoma ?
  • Out of all 7MM countries, which country would have the highest prevalent population of Metastatic Merkel Cell Carcinoma during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Metastatic Merkel Cell Carcinoma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Metastatic Merkel Cell Carcinoma in the USA, Europe, and Japan?
  • What are the Metastatic Merkel Cell Carcinoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Metastatic Merkel Cell Carcinoma ?
  • How many therapies are developed by each company for Metastatic Merkel Cell Carcinoma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Metastatic Merkel Cell Carcinoma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Metastatic Merkel Cell Carcinoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Metastatic Merkel Cell Carcinoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Metastatic Merkel Cell Carcinoma ?
  • What are the global historical and forecasted market of Metastatic Merkel Cell Carcinoma ?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Merkel Cell Carcinoma market
  • To understand the future market competition in the Metastatic Merkel Cell Carcinoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Metastatic Merkel Cell Carcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Metastatic Merkel Cell Carcinoma market
  • To understand the future market competition in the Metastatic Merkel Cell Carcinoma market

Table of Contents

1. Key Insights

2. Executive Summary of Metastatic Merkel Cell Carcinoma

3. Competitive Intelligence Analysis for Metastatic Merkel Cell Carcinoma

4. Metastatic Merkel Cell Carcinoma : Market Overview at a Glance

  • 4.1. Metastatic Merkel Cell Carcinoma Total Market Share (%) Distribution in 2017
  • 4.2. Metastatic Merkel Cell Carcinoma Total Market Share (%) Distribution in 2030

5. Metastatic Merkel Cell Carcinoma : Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Metastatic Merkel Cell Carcinoma Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Metastatic Merkel Cell Carcinoma Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Metastatic Merkel Cell Carcinoma Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Metastatic Merkel Cell Carcinoma Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Metastatic Merkel Cell Carcinoma Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Metastatic Merkel Cell Carcinoma Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Metastatic Merkel Cell Carcinoma Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Metastatic Merkel Cell Carcinoma Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Metastatic Merkel Cell Carcinoma Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Metastatic Merkel Cell Carcinoma Treatment and Management
  • 8.2. Metastatic Merkel Cell Carcinoma Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Metastatic Merkel Cell Carcinoma Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Metastatic Merkel Cell Carcinoma : Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Metastatic Merkel Cell Carcinoma Market Size in 7MM
  • 13.3. Metastatic Merkel Cell Carcinoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Metastatic Merkel Cell Carcinoma Total Market Size in the United States
    • 15.1.2. Metastatic Merkel Cell Carcinoma Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Metastatic Merkel Cell Carcinoma Total Market Size in Germany
    • 15.3.2. Metastatic Merkel Cell Carcinoma Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Metastatic Merkel Cell Carcinoma Total Market Size in France
    • 15.4.2. Metastatic Merkel Cell Carcinoma Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Metastatic Merkel Cell Carcinoma Total Market Size in Italy
    • 15.5.2. Metastatic Merkel Cell Carcinoma Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Metastatic Merkel Cell Carcinoma Total Market Size in Spain
    • 15.6.2. Metastatic Merkel Cell Carcinoma Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Metastatic Merkel Cell Carcinoma Total Market Size in the United Kingdom
    • 15.7.2. Metastatic Merkel Cell Carcinoma Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Metastatic Merkel Cell Carcinoma Total Market Size in Japan
    • 15.8.3. Metastatic Merkel Cell Carcinoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Metastatic Merkel Cell Carcinoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

List of Tables

  • Table 1: 7MM Metastatic Merkel Cell Carcinoma Epidemiology (2017-2030)
  • Table 2: 7MM Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases (2017-2030)
  • Table 3: Metastatic Merkel Cell Carcinoma Epidemiology in the United States (2017-2030)
  • Table 4: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Metastatic Merkel Cell Carcinoma Epidemiology in Germany (2017-2030)
  • Table 6: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Metastatic Merkel Cell Carcinoma Epidemiology in France (2017-2030)
  • Table 8: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Metastatic Merkel Cell Carcinoma Epidemiology in Italy (2017-2030)
  • Table 10: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Metastatic Merkel Cell Carcinoma Epidemiology in Spain (2017-2030)
  • Table 12: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Metastatic Merkel Cell Carcinoma Epidemiology in the UK (2017-2030)
  • Table 14: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15: Metastatic Merkel Cell Carcinoma Epidemiology in Japan (2017-2030)
  • Table 16: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20: Region-wise Market Size in USD, Million (2017-2030)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22: United States Market Size in USD, Million (2017-2030)
  • Table 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24: Germany Market Size in USD, Million (2017-2030)
  • Table 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26: France Market Size in USD, Million (2017-2030)
  • Table 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28: Italy Market Size in USD, Million (2017-2030)
  • Table 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30: Spain Market Size in USD, Million (2017-2030)
  • Table 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34: Japan Market Size in USD, Million (2017-2030)
  • Table 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Metastatic Merkel Cell Carcinoma Epidemiology (2017-2030)
  • Figure 2: 7MM Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases (2017-2030)
  • Figure 3: Metastatic Merkel Cell Carcinoma Epidemiology in the United States (2017-2030)
  • Figure 4: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Metastatic Merkel Cell Carcinoma Epidemiology in Germany (2017-2030)
  • Figure 6: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Metastatic Merkel Cell Carcinoma Epidemiology in France (2017-2030)
  • Figure 8: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Metastatic Merkel Cell Carcinoma Epidemiology in Italy (2017-2030)
  • Figure 10: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Metastatic Merkel Cell Carcinoma Epidemiology in Spain (2017-2030)
  • Figure 12: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Metastatic Merkel Cell Carcinoma Epidemiology in the UK (2017-2030)
  • Figure 14: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15: Metastatic Merkel Cell Carcinoma Epidemiology in Japan (2017-2030)
  • Figure 16: Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20: Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22: United States Market Size in USD, Million (2017-2030)
  • Figure 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24: Germany Market Size in USD, Million (2017-2030)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26: France Market Size in USD, Million (2017-2030)
  • Figure 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28: Italy Market Size in USD, Million (2017-2030)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30: Spain Market Size in USD, Million (2017-2030)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34: Japan Market Size in USD, Million (2017-2030)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of figures is not exhaustive; the final content may vary.